Evans David R H, Romero Jonathan K, Westoby Matthew
Biopharmaceutical Development, Biogen Idec. Inc., Cambridge, Massachusetts, USA.
Methods Enzymol. 2009;463:97-120. doi: 10.1016/S0076-6879(09)63009-3.
The dramatic advances in recombinant DNA and proteomics technology over the past decade have supported a tremendous growth in biologics applied to diagnostics, biomarkers, and commercial therapeutic markets. In particular, antibodies and fusion proteins have now become a main focus for a broad number of clinical indications, including neurology, oncology, and infectious diseases with projected increase in novel first-class molecules and biosimilar entities over the next several years. In line with these advances are the improved analytical, development, and small-scale preparative methods employed to elucidate biologic structure, function, and interaction. A number of established methods are used for solvent removal, including lyophilization, reverse extraction, solute precipitation, and dialysis (solvent exchange), ultrafiltration, and chromatographic techniques. Notably, advances in the miniaturization and throughput of protein analysis have been supported by the development of a plethora of microscale extraction procedures and devices that exploit a wide array of modes for small-scale sample preparation, including the concentration and desalting of protein samples prior to further analysis. Furthermore, advances in process handling and data monitoring at microscale have dramatically improved complex control and product recovery of small quantities of biologics using techniques such as lyophilization and precipitation. In contrast, the efficient concentration of feed streams during preparative chromatography has been enhanced by improvements to protein binding capacity achieved through advanced bead and ligand design. The objective of solvent removal may be to prepare or concentrate solutes for analysis, or to facilitate their production or modification. Here, we describe the most recent advances in these techniques, particularly focusing on improved capabilities for bench-scale preparative methods.
在过去十年中,重组DNA和蛋白质组学技术取得了巨大进展,推动了应用于诊断、生物标志物和商业治疗市场的生物制品的迅猛增长。特别是,抗体和融合蛋白现已成为众多临床适应症的主要关注点,包括神经病学、肿瘤学和传染病,预计在未来几年新型一流分子和生物类似物实体将有所增加。与这些进展相一致的是,用于阐明生物结构、功能和相互作用的分析、开发和小规模制备方法也得到了改进。有多种既定方法可用于去除溶剂,包括冻干、反向萃取、溶质沉淀、透析(溶剂交换)、超滤和色谱技术。值得注意的是,蛋白质分析的小型化和通量的提高得益于大量微尺度萃取程序和设备的开发,这些程序和设备利用多种模式进行小规模样品制备,包括在进一步分析之前对蛋白质样品进行浓缩和脱盐。此外,微尺度下工艺处理和数据监测的进展显著改善了使用冻干和沉淀等技术对少量生物制品的复杂控制和产物回收。相比之下,通过先进的珠子和配体设计提高蛋白质结合能力,增强了制备色谱过程中进料流的有效浓缩。去除溶剂的目的可能是为了制备或浓缩溶质以进行分析,或者是为了促进它们的生产或修饰。在此,我们描述了这些技术的最新进展,尤其关注台式规模制备方法的改进能力。